Validation of a staging system for evaluating prognosis in prostate cancer

Connecticut Medicine

Volumn 64, Issue 8, 2000, Pages 459-464

  Anderson, Daren R ^a   Patil, Sujata ^a   Kamina, Ayumi ^a   Penson, David F ^a   Peduzzi, Peter ^a   Concato, John ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD; CANCER STAGING; COHORT ANALYSIS; EVALUATION; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; SURVIVAL;

ADULT; AGED; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0034243935     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Barry MJ, Fleming C, Coley CM, et al: Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: Management strategies and outcomes. Urology 1995; 46:277-89.
2. Franks LM: Latent carcinoma of the prostate. J Pathol Bacteriol 1954; 68:603-16.
3. Sakr WA, Haas GP, Cassin BF, et al: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993; 150:379-85.
4. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics 1998. Cancer J Clin 1998; 48:6-29.
5. Litwin MS, Hays RD, Fink A, et al: Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995; 273:129-35.
6. Fowler FJJ, Barry MJ, Lu-Yao G, et al: Effect of radical prostatectomy for prostate cancer on patient quality of life: Results from a Medicare survey. Urology 1995; 45:1007-15.
7. Shrader-Bogen CL, Kjellberg JL, McPherson CP, Murray CL: Quality of life and treatment outcomes. Cancer 1997; 79:1977-86.
8. Zagars GK, Pollack A, von Eschenbach AC: Prognostic factors for clinically localized prostate carcinoma. Cancer 1997; 79:1370-80.
9. Pisansky TM, Kahn MJ, Rasp GM, et al: A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer 1997; 79:337-44.
10. Lerner SE, Blute ML, Bergstralh EJ, et al: Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol 1996; 156:137-143.
11. Roach Mr, Marquez C, Yuo HS, et al: Predicting the risk of lymph node involvement using the pretreatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994; 28:33-7.
12. Narayan P, Fournier G, Gajendran V, et al: Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastasis in prostate cancer. Urology 1994; 44:519-24.
13. Bluestein DL, Bostwick DG, Bergstralh EJ, Oesterling JE: Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol 1994; 151:1315-20.
14. Clemens JD, Feinstein AR, Holabird N, Cartwright S: A new clinical-anatomic staging system for evaluating prognosis and treatment of prostatic cancer. J Chron Dis 1986; 1986:913-28.
15. Peipert JF, Wells CK, Schwartz PE, Feinstein AR: The impact of symptoms and comorbidity on prognosis in stage 1B cervical cancer. Am J Obstet Gynecol 1993; 169:598-604.
16. Feinstein A, Wells C: A clinical-severity staging system for patients with lung cancer. Medicine 1990; 69:1-33.
17. Charlson ME, Feinstein AR: The auxometric dimension. A new method for using rate of growth in prognostic staging of breast cancer. JAMA 1974; 228:180-5.
18. Piccirillo JF, Sasake CT, Wells CK, Feinstein AR: New clinical severity staging system for cancer of the larynx. Ann Otol Rhinol Laryngol 1994; 103:83-92.
19. Feinstein AR, Schimpff CR, Hull EW: A reappraisal of staging and therapy for patients with cancer of the rectum. I. Development of two new systems of staging. Arch Intern Med 135; 135:1441-53.
20. Feinstein AR, Schimpff CR, Hull EW: A reappraisal of staging and therapy for patients with cancer of the rectum. II. Patterns of presentation and outcome of treatment. Arch Intern Med 1975; 135:1454-62.
21. Wells CK, Stoller JK, Feinstein AR, Horwitz RI: Comorbid and clinical determinants of prognosis in endometrial cancer. Arch Intern Med 1984; 144:2004-9.
22. Boyd NF, Clemens JD, Feinstein AR: Pretherapeutic morbidity in the prognostic staging of acute leukemia. Arch Intern Med 1979; 139:324-328.
23. Taylor WF, Ivins JC, Unni KK, et al: Prognostic variables in osteosarcoma: A multi-institutional study. J Natl Cancer Inst 1989;81:21-30.
24. Neel HB, Taylor WF: New staging system for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 1989;115:1293-1303.
25. Neel HB, Taylor WF, Pearson GR: Prognostic determinants and a new view of staging for patients with nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol 1985; 94:529-37.
26. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 1987; 40:373-83.
27. Lerner SE, Seay TM, Blute ML, et al: Prostate specific antigen detected prostate cancer (clinical stage T1c): An interim analysis. J Urol 1996; 155:821-6.
28. Catalona WJ, Smith DS: Five-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152:1837-42.
29. Zietman AL, Edelstein RA, Coen JJ, et al: Radical prostatectomy for adenocarcinoma of the prostate: The influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 1994; 43:828-33.
30. Geara FB, Zagars GK, Pollack A: Influence of initial presentation on treatment outcome of clinically localized prostate cancer treated by definitive radiation therapy. Int J Radiat Oncol Biol Phys 1994; 30:331-7.
31. Kuban DA, El-Mahdi AM, Schellhammer PF: Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 1995; 32:307-16.
32. Albertsen PC, Fryback DG, Storer BE, et al: The impact of comorbidity on life expectancy among men with localized prostate cancer. J Urol 1996; 156:127-32.
33. Albertsen PC, Fryback DG, Storer BE, et al: Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274:626-31.
34. Kupelian PA, Katcher J, Levin HS, Klein EA: Stage T1-2 prostate cancer: A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997; 37:1043-52.
35. Matzkin H, Perito PE, Soloway MS: Prognostic factors in metastatic prostate cancer. Cancer 1993; 72:3788-92.
36. Kleer E, Larson-Keller JJ, Zincke H, Oesterling JE: Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade. Urology 1993; 41:207-16.
37. Partin AW, Yoo J, Carter HB, et al: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110-14.
38. Partin AW, Kattan MW, Subong EN, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277:1445-51.